Lowering the Barriers to Biotech: How Douglas Crawford Built an Engine for Scientific Entrepreneurs

In an exclusive conversation ahead of his appearance at SynBioBeta 2026 on May 4–7 in San Jose, Douglas Crawford describes a career defined by a single, consistent mission.

“I have been singularly focused on helping scientific entrepreneurs turn their promising ideas into promising companies,” he says.

For Crawford, that focus has shaped more than two decades of work building infrastructure for biotech founders. The result is MBC BioLabs, a network of shared laboratories that has helped launch over 500 companies, initiate 176 clinical trials, and bring more than 135 products to market.

Today, MBC BioLabs is a central node in the biotech startup ecosystem. Its facilities provide shared laboratory infrastructure, scientific equipment, and a built-in community of founders, allowing early-stage companies to move from concept to proof of principle far more quickly than traditional lab models allow.

The origins of that model trace back to a small experiment. In 2007, while helping launch the QB3 Garage at UCSF, the first technology incubator in the University of California system, Crawford faced a simple decision. He could lease the available space to a single company, or divide it into smaller bench units and host multiple founders at once. He chose the latter.

“That meant that if a scientific entrepreneur wanted to generate company data, they could do this even if their only source of capital was a credit card,” he recalls.

None of the six initial startups in the QB3 Garage had venture capital. Within two years, four had raised funding and a fifth was acquired by Affymetrix directly out of the space. The experiment demonstrated that lowering the cost of entry dramatically increased the number of scientific bets that can be taken.

That principle remains central to MBC BioLabs today. Startups gain immediate access to laboratory space, shared scientific instrumentation worth millions of dollars, and a network of mentors, investors, and fellow founders. This lets scientists focus on building companies rather than building laboratories.

“The idea remains to create a space where two scientists with a credit card can start a company,” Crawford says.

The model has scaled dramatically and successfully. Companies launched within the MBC BioLabs ecosystem have collectively raised more than $20 billion in capital. Many synthetic biology pioneers, including Alpine Bio, Wild Type, Ripple Foods, and Zymergen, began developing their technologies at MBC.

Crawford evaluates prospective startups based on three criteria. Deep expertise in their field, a commitment to tackling a large problem, and the ability to contribute to a collaborative environment. Community, he argues, is the organization’s most valuable asset.

“When founders leave us, it’s the community they miss most,” he says. Many arrive focused on cost and equipment access. Years later, what they remember are the hallway conversations and informal exchanges that helped shape their companies.

The broader biotech environment has also shifted in recent years. While scientific innovation continues to accelerate, funding conditions for early-stage companies have tightened. Many generalist investors who entered life sciences during the pandemic have retreated, leaving founders navigating a more constrained capital landscape.

Crawford is direct about the challenge.

“This is a tough time to raise money,” he says. “Fortunately, the flexibility of our space allows our community members to optimize their efficiency as they weather these trying times.”

The ability to expand gradually, adding space bench by bench as a company grows, has become more than a convenience. For many startups, it is a way to extend runway and maintain momentum while navigating uncertain funding cycles.

Crawford’s perspective is shaped not only by his work at MBC BioLabs but also by his role as Managing Partner at Mission BioCapital. The venture firm closed a $275 million fund in 2021 and invests in early-stage life science companies. Crawford has overseen investments in dozens of startups across therapeutics, diagnostics, and synthetic biology, including companies such as Alector, Principia Biopharma, and Redwood Biosciences.

Despite the scale of these efforts, Crawford’s core mission has remained remarkably consistent since the early days of the QB3 Garage: give scientists a realistic path to building companies.

He hopes more academic researchers will view entrepreneurship as a natural extension of their work. The infrastructure now exists to make that transition far less daunting than it once was.

“Every entrepreneurial scientist with a dream should be given a chance,” Crawford says.

If the next wave of synthetic biology breakthroughs emerges from startup laboratories rather than traditional institutions, Crawford’s quiet experiment in shared infrastructure may prove to be one of the field’s most important enabling technologies.

His message to scientists sitting on promising ideas is straightforward. The leap from bench to company does not always require a venture term sheet or a fully built laboratory.

Sometimes, he says, a single lab bench is enough.